5th General Assembly & Patient Event of the QSPainRelief Consortium, Leiden, The Netherlands, at the Centre for Human Drug Research
December 5-7, 2022
4th General Assembly Meeting of the QSPainRelief Consortium, Barcelona
June 23-24, 2022
Steering Committee Meeting of the QSPainRelief Consortium (held remotely)
May 24-25, 2022
Steering Committee Meeting of the QSPainRelief Consortium, Munich
December 13-15, 2021
3rd General Assembly Meeting of the QSPainRelief Consortium (held remotely)
July 13-14, 2021
Steering Committee Meeting of the QSPainRelief Consortium (held remotely)
December 9-10, 2020
2nd General Assembly Meeting of the QSPainRelief Consortium (held remotely)
Feb 19-Feb 21, 2020
ISB participated in a panel discussion on “Artificial Intellegience and Machine Learning in CNS Clinical Trials” for the International Society for CNS Trial Methodologies, Washington, DC
January 22-24, 2020
Kick-off Meeting of the QSPainRelief Consortium, Leiden
Dec 4-Dec 7, 2019
Clinical Trials in Alzheimer’s Disease Meeting in San Diego, CA
ISB co-organized a symposium on “NEW PREDICTIVE PLATFORMS FOR ADVANCING DRUG COMBINATION APPROACHES FOR ALZHEIMER PATHOLOGY”
Program: Prof Lon Schneider (UCSF) chairs a session with Richard Kennedy (Univ of Alabama) on “In Silico Screening of Medications for Slowing Alzheimer’s Disease Progression in a Clinical Trials Meta-database”, Tom Anastasiou (Univ of Illinois) on “Drug Combination Identification through Correlation between a Clinical Dataset and a Computational Model ” and Hugo Geerts (In Silico Biosciences) on “Evaluating pharmacodynamic interactions in drug combinations using Quantitative Systems Pharmacology analysis of clinical trials.”
Oct 31-Nov 3, 2019
On invitation, ISB presents “QUANTITATIVE SYSTEMS PHARMACOLOGY AS A HUMAN AUGMENTED INTELLIGENCE TOOL FOR CNS R&D”
CNS Summit, Boca Raton, FL
Oct 20-23, 2019
American Conference on Pharmacometrics, Orlando, FL
ISB presents poster on “UNDERSTANDING CLINICAL OUTCOME OF ADUCANUMAB TRIALS IN ALZHEIMER USING A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL”
